Clinical trials
Connective Tissue Diseases trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 7 |
| Active, not recruiting | 5 |
| Enrolling by invitation | 3 |
| Unknown status | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Viatris Innovation GmbH | 3 |
| Bristol-Myers Squibb | 2 |
| Central Hospital, Nancy, France | 2 |
| Centre Hospitalier Universitaire de Nice | 2 |
| GlaxoSmithKline | 2 |
| United Therapeutics | 2 |
| University Hospital, Brest | 2 |
| AbbVie | 1 |
| Amgen | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Connective Tissue Diseases | 28 |
| Lupus Erythematosus, Systemic | 9 |
| Autoimmune Diseases | 8 |
| Immune System Diseases | 8 |
| Lung Diseases, Interstitial | 6 |
| Pulmonary Arterial Hypertension | 4 |
| Scleroderma, Diffuse | 4 |
| Scleroderma, Systemic | 4 |
| Arthritis, Rheumatoid | 3 |
| Familial Primary Pulmonary Hypertension | 3 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.